Marker for statin treatment stratification in heart failure
The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.
1. A method of treating a human patient having heart failure comprising:
(a) combining a serum or plasma sample from a patient with an antibody or antibodies capable of detection and specific for a biomarker wherein the biomarker is one or more of the following: SHBG (Sex Hormone-Binding Globulin), PLGF (Placental Growth Factor), and/or IL-6 (Interleukin-6);
(b) detecting the antibody/biomarker complex to determine a level of the at least one biomarker selected from SHBG (Sex Hormone-Binding Globulin), PLGF (Placental Growth Factor), IL-6 (Interleukin-6), in the sample;
(c) comparing the level of the at least one marker to a respective reference level;
(d) identifying the patient as more likely to respond to a therapy comprising a statin when the level of the at least one biomarker is indicative for a therapy comprising a statin; and
(e) administering a statin to the identified patient.
2. The method according to claim 1 , wherein the subject has heart failure classified as stage B, C or D according to the ACC/AHA classification, and/or wherein the subject has heart failure classified as NYHA class II, III or IV according to the NYHA classification.
3. The method according to claim 1 , wherein the patient also has coronary artery disease.
4. The method of claim 1 , wherein
i) the at least one biomarker is SHBG, and
a) wherein the patient does not suffer from coronary artery disease, and wherein a level of the biomarker in the sample from the patient below the reference level indicates that the patient is more likely to respond to the therapy comprising a statin, and/or wherein a level of the biomarker in the sample from the patient above the reference level indicates that the patient is less likely to respond to the therapy comprising a statin, or
b) wherein the patient suffers from coronary artery disease, and wherein a level of the biomarker in the sample from the patient above the reference level indicates that the patient is more likely to respond to the therapy comprising a statin, and/or wherein a level of the biomarker in the sample from the patient below the reference level indicates that the patient is less likely to respond to the therapy comprising a statin and/or
ii) the at least one biomarker is PlGF, and wherein a level of the biomarker in the sample from the patient above the reference level indicates that the patient is more likely to respond to the therapy comprising a statin, and/or wherein a level of the biomarker in the sample from the patient below the reference level indicates that the patient is less likely to respond to the therapy comprising a statin, and/or
the at least one biomarker is IL-6, and wherein a level of the biomarker in the sample from the patient above the reference level indicates that the patient is more likely to respond to the therapy comprising a statin, and/or wherein a level of the biomarker in the sample from the patient below the reference level indicates that the patient is less likely to respond to the therapy comprising a statin.
5. The method of claim 1 further comprising a step wherein therapy with a statin is initiated or continued if the patient has been identified as likely to respond to a therapy comprising a statin.
6. The method of claim 1 , wherein the biomarker measured is SHBG (Sex Hormone-Binding Globulin).
7. The method of claim 1 , wherein the biomarker measured is PLGF (Placental Growth Factor).
8. The method of claim 1 , wherein the biomarker measured is IL-6 (Interleukin-6).
9. The method according to claim 1 , wherein the subject has heart failure classified as stage B or C according to the ACC/AHA classification, and/or wherein the subject has heart failure classified as NYHA class II or III according to the NYHA classification.
10. The method according to claim 1 , wherein the patient also has coronary artery disease and wherein the at least one biomarker is PlGF.